BACKGROUND: The complete resection of liver metastases from colorectal cancer is the major determinant of longterm survival. The effectiveness of current chemotherapy regimens has made treatment algorithms more flexible and resulted in many different options. Recently, the pathological response to chemotherapy has emerged as another important prognostic marker. Different systems have been used to grade the pathological response in these patients. METHODS: This study prospectively evaluates the prognostic value of the pathological response grade (PRG) in liver metastases treated with neoadjuvant chemotherapy. RESULTS: Between 2002 and 2006, 50 patients were treated with a sandwich chemotherapy regimen and underwent liver resection. Complete resection was achieved in 45 patients (90%). A strong pathological response to chemotherapy (<10% viable tumour cells in all lesions) was seen in 17 patients (34%). It was associated with a statistically significant longer overall survival (P= 0.019) and was also identified on multivariate analysis as an independent predictor of survival (odds ratio = 243). CONCLUSIONS: This pilot study demonstrates the prognostic potential of the PRG, which could be used clinically to select patients for an aggressive multimodal adjuvant algorithm. Larger multicentre studies are required to validate this particular grading system. The keys to longterm survival are resectability and chemo-responsiveness.
BACKGROUND: The complete resection of liver metastases from colorectal cancer is the major determinant of longterm survival. The effectiveness of current chemotherapy regimens has made treatment algorithms more flexible and resulted in many different options. Recently, the pathological response to chemotherapy has emerged as another important prognostic marker. Different systems have been used to grade the pathological response in these patients. METHODS: This study prospectively evaluates the prognostic value of the pathological response grade (PRG) in liver metastases treated with neoadjuvant chemotherapy. RESULTS: Between 2002 and 2006, 50 patients were treated with a sandwich chemotherapy regimen and underwent liver resection. Complete resection was achieved in 45 patients (90%). A strong pathological response to chemotherapy (<10% viable tumour cells in all lesions) was seen in 17 patients (34%). It was associated with a statistically significant longer overall survival (P= 0.019) and was also identified on multivariate analysis as an independent predictor of survival (odds ratio = 243). CONCLUSIONS: This pilot study demonstrates the prognostic potential of the PRG, which could be used clinically to select patients for an aggressive multimodal adjuvant algorithm. Larger multicentre studies are required to validate this particular grading system. The keys to longterm survival are resectability and chemo-responsiveness.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Tamara L Znajda; Shinichi Hayashi; Peter J Horton; John B Martinie; Prosanto Chaudhury; Victoria A Marcus; Jeremy R Jass; Peter Metrakos Journal: J Gastrointest Surg Date: 2006-04 Impact factor: 3.452
Authors: Mehrdad Nikfarjam; Serene Shereef; Eric T Kimchi; Niraj J Gusani; Yixing Jiang; Diego M Avella; Rickhesvar P Mahraj; Kevin F Staveley-O'Carroll Journal: Ann Surg Oncol Date: 2008-11-27 Impact factor: 5.344
Authors: Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron Journal: Ann Surg Date: 2002-06 Impact factor: 12.969
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Jennica K S Ng; Stefan J Urbanski; Naurang Mangat; Andrew McKay; Francis R Sutherland; Elijah Dixon; Scot Dowden; Scott Ernst; Oliver F Bathe Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Birgit Gruenberger; Werner Scheithauer; Robert Punzengruber; Christoph Zielinski; Dietmar Tamandl; Thomas Gruenberger Journal: BMC Cancer Date: 2008-04-25 Impact factor: 4.430
Authors: M L Gómez Dorronsoro; R Vera; L Ortega; C Plaza; R Miquel; M García; E Díaz; M R Ortiz; J Pérez; C Hörndler; C Villar; J Antúnez; S Pereira; F López-Rios; R González-Cámpora Journal: Clin Transl Oncol Date: 2013-09-10 Impact factor: 3.405
Authors: R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras Journal: Clin Transl Oncol Date: 2013-12-12 Impact factor: 3.405
Authors: René Adam; Aimery De Gramont; Joan Figueras; Ashley Guthrie; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Josep Tabernero; Catherine Teh; Eric Van Cutsem Journal: Oncologist Date: 2012-09-07
Authors: Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele Journal: J Cancer Date: 2014-01-01 Impact factor: 4.207
Authors: Carrie Howard; Thomas W Clements; Janet P Edwards; Anthony R MacLean; W Donald Buie; Elijah Dixon; Sean C Grondin; Anthony Gomes; Michael McColl; Sean P Cleary; Shiva Jayaraman; Renelle Daigle; Chad G Ball Journal: Hepatobiliary Surg Nutr Date: 2018-08 Impact factor: 7.293